Navigation Links
Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
Date:11/23/2007

AMSTERDAM, November 23 /PRNewswire/ -- Kiadis Pharma announces today that there will be three presentations on its products ATIR and Rhitol in poster sessions at the 2007 Annual Meeting of the American Society of Hematology (ASH) December 8-11 in Atlanta, Georgia, USA. Data will be presented from the companies ongoing clinical study on ATIR by its principal investigator Dr. Denis Claude Roy, who also presents data on the functionality of Rhitol. In addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the NIH.

ATIR: presentation of clinical phase I/II study on mismatched transplantations by Dr. Denis-Claude Roy

Title poster: "Phase I/II clinical trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher doses of Donor Lymphocyte Infusions depleted of Alloreactive Cells using ATIR may improve outcome without causing GvHD

- Abstract #2976; Poster 2976, Board #195-III (10 December,5-7 pm)

Dr. Denis Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "Our results indicate that the post-transplant infusion of a ATIR-PDT treated DLI is feasible, does not induce acute GVHD, and suggests a clinical benefit for patients receiving the highest DLI doses to accelerate T cell reconstitution. This PDT strategy represents an appealing alternative for older patients and those at high risk for GVHD"

Rhitol: presentation on functionality of Rhitol in chronic GvHD by Dr. Denis-Claude Roy

Title poster: " anti-Chronic Graft Versus Host Disease activity through a regulatory T Cell dependent mechanism after photodynamic therapy.

- Abstract #3280; Poster 3280; Board #499-III (10 December,5-7 pm)

Dr. Denis-Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "our results demonstrate that TH9402 PDT not only eliminates activated T cells, but preserves Tregs, with the functional ability to inhibit
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... screened positive for a history of hazardous or binge ... percent after receiving mobile phone text messages following a ... published online yesterday in Annals of Emergency Medicine ... Adult Emergency Department Patients: A Randomized Clinical Trial "). ... adults ages 18 to 24 visit ERs and up ...
(Date:7/11/2014)... 11, 2014 With the arrival of ... seeking cosmetic surgery and hair transplant procedures, up 80 ... expansive range of medical tourism destinations, the company is ... costs and achieve the look they have always ... the top name in the medical tourism industry, VisitandCare.com ...
(Date:7/11/2014)... By Steven Reinberg ... -- Stress, hostility and depression may increase the risk for ... depression seemed to raise the risk of a stroke or ... also found that stress apparently raised stroke or TIA risk ... said. A TIA is a mini-stroke caused by a temporary ...
(Date:7/11/2014)... July 11, 2014 Fadhits.com, the distinguished ... elegant assortment of lace holiday dresses . To ... are now offered at discounted prices, up to 65% ... can enjoy this special offer. , Fadhits.com is ... special occasion dresses for the global clients. All its ...
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
Breaking Medicine News(10 mins):Health News:Text message medicine: Texts from the ER can reduce binge drinking 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2
... ... their products stocked in more than 10,000 retail outlets nationwide working closely with major ... ... brand Intellicig has signed an exclusive deal which will see their products stocked in ...
... , , , BEIJING , ... SVA),("Sinovac" or the "Company"), a leading China -based vaccine ... was,closed on February 2, 2010 . Sinovac received net ... and commissions and,estimated offering expenses payable by the Company, which ...
... , NASHVILLE, Tenn. , Feb. 2 ... its common stock cash dividend for the quarter ended December ... per share, is payable on March 4, 2010 ... , Healthcare Realty Trust is a real estate investment trust that ...
... PHILADELPHIA - For the first time, researchers from the ... three different degenerative brain disorders are linked by a ... Elk-1, was found in clumps of misshaped proteins that ... Huntington,s disease. "These results suggest a molecular ...
... ... accreditation to the Oakland University William Beaumont School of Medicine. , ... (Vocus) February 2, 2010 -- The Liaison ... Beaumont School of Medicine ., , , , ,The LCME is the national accrediting authority ...
... one scan is usually enough, but editorial begs to differ ... a paper in a medical journal to be accompanied by ... might be "overly simple and consequently not clinically useful." , ... 3 issue of the Journal of the American Medical ...
Cached Medicine News:Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 2Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 3Health News:Sinovac Announces Closing of Common Share Offering 2Health News:Sinovac Announces Closing of Common Share Offering 3Health News:Healthcare Realty Trust Announces Fourth Quarter Dividend 2Health News:3 brain diseases linked by toxic form of same neural protein 2Health News:Oakland University William Beaumont School of Medicine Reaches Development Milestone 2Health News:Analysis Examines Ultrasound Use for Blood Clots 2Health News:Analysis Examines Ultrasound Use for Blood Clots 3
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... indicate early non-responders unlikely to subsequently,respond, have ... earlier change in treatment strategy, COLORADO SPRINGS, ... presented at the 2007 International Congress on,Schizophrenia ... assessed earlier than is presently thought, and,challenge ...
... Time Reduced By an Average of More ... PARK, N.C., April 02, 2007 /PRNewswire/ --,Adding ... XL 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing ... patients to continue,their daily activities for a ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Slip on, warm with a ... to fit. Splint hardens as ... and reposition. Unique fiberglass knit ... polymer Straps included. Tape, 1" ...
... The Blue Line ThumStay offers thumb and ... with soft, breathable foam. Lightweight stays provide ... and can easily be contoured for proper ... with deQuervain's tenosynovitis, tendinitis, CMC joint arthritis, ...
Medicine Products: